Transgene Biotek Limited announced audited standalone and consolidated earnings results for the fourth quarter and full year ended March 31, 2020. For the quarter, on standalone basis, the company reported total income of INR 438,470 compared to INR 19,062,368 a year ago. Loss for the period was INR 27,869,929 compared to INR 9,021,660 a year ago. Basic and diluted loss per share was INR 0.4 compared to INR 0.1 a year ago. For the year, on standalone basis, the company reported total income of INR 1,824,574 compared to INR 21,090,648 a year ago. Loss for the period was INR 109,622,372 compared to INR 87,927,135 a year ago. Basic and diluted loss per share was INR 1.4 compared to INR 1.2 a year ago. For the quarter, on consolidated basis, the company reported total income of INR 438,470 compared to INR 19,062,368 a year ago. Loss for the period was INR 27,869,929 compared to INR 9,021,660 a year ago. Basic and diluted loss per share was INR 0.4 compared to INR 0.1 a year ago. For the year, on consolidated basis, the company reported total income of INR 1,824,574 compared to INR 21,090,648 a year ago. Loss for the period was INR 109,622,372 compared to INR 87,927,135 a year ago. Basic and diluted loss per share was INR 1.4 compared to INR 1.2 a year ago.